{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T05:29:36Z","timestamp":1785648576100,"version":"3.56.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jcin.2022.09.053","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T14:02:55Z","timestamp":1671026575000},"page":"19-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention"],"prefix":"10.1016","volume":"16","author":[{"given":"Ko","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Obayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Natsuaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Yamaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenori","family":"Domei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ogita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Ohya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shojiro","family":"Tatsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nikaido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenjin","family":"Nishikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7731-5308","authenticated-orcid":false,"given":"Nobuhiro","family":"Suematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujio","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Komiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Shigematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Isawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Suwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2022.09.053_bib1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2022.09.053_bib2","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2022.09.053_bib3","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2022.09.053_bib4","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2022.09.053_bib5","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jcin.2022.09.053_bib6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41569-022-00725-6","article-title":"P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jcin.2022.09.053_bib7","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.jcin.2022.09.053_bib8","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.09.053_bib9","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1253\/circj.CJ-19-1109","article-title":"JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease","volume":"84","author":"Nakamura","year":"2020","journal-title":"Circ J"},{"key":"10.1016\/j.jcin.2022.09.053_bib10","doi-asserted-by":"crossref","first-page":"n1332","DOI":"10.1136\/bmj.n1332","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials","volume":"373","author":"Valgimigli","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jcin.2022.09.053_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12170-014-0430-5","article-title":"State-of-the-art: hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus","volume":"9","author":"Kumbhani","year":"2015","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"10.1016\/j.jcin.2022.09.053_bib12","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1161\/CIRCULATIONAHA.120.045465","article-title":"Antithrombotic therapy for atherosclerotic cardiovascular disease risk mitigation in patients with coronary artery disease and diabetes mellitus","volume":"142","author":"Capodanno","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2022.09.053_bib13","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","article-title":"Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease","volume":"64","author":"Angiolillo","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.09.053_bib14","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.jacc.2008.07.068","article-title":"Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex\u00a0vivo","volume":"52","author":"Erlinge","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.09.053_bib15","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00228-018-2530-5","article-title":"Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19\u22172 genotype?","volume":"74","author":"Chouchene","year":"2018","journal-title":"Eur J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jcin.2022.09.053_bib16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jacc.2006.03.038","article-title":"Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment","volume":"48","author":"Angiolillo","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.09.053_bib17","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","article-title":"Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"11","author":"Levine","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jcin.2022.09.053_bib18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2\u00a0months of dual antiplatelet therapy with 12\u00a0months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jcin.2022.09.053_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.122.012004","article-title":"Clopidogrel monotherapy after 1-month dual antiplatelet therapy in percutaneous coronary intervention: from the STOPDAPT-2 Total Cohort","volume":"15","author":"Obayashi","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2022.09.053_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","article-title":"Thrombolysis In Myocardial Infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase","volume":"11","author":"Rao","year":"1988","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.09.053_bib21","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2022.09.053_bib22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining\u00a0high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2022.09.053_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.atherosclerosis.2020.01.002","article-title":"Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: pre-specified subgroup analysis from the randomized GLOBAL LEADERS study","volume":"295","author":"Chichareon","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jcin.2022.09.053_bib24","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.jacc.2020.03.008","article-title":"Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention","volume":"75","author":"Angiolillo","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.09.053_bib25","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/cpt.1496","article-title":"Modulation of CYP450 activities in patients with type 2 diabetes","volume":"106","author":"Gravel","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2022.09.053_bib26","first-page":"763","article-title":"Pharmacodynamic effects of vorapaxar in patients with and without diabetes mellitus: results of the OPTIMUS-5 study","volume":"4","author":"Franchi","year":"2019","journal-title":"J\u00a0Am Coll Cardiol Basic Trans Science"},{"key":"10.1016\/j.jcin.2022.09.053_bib27","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/eurheartj\/ehq494","article-title":"A\u00a0pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing Anti-Platelet Therapy in Diabetes Mellitus (OPTIMUS)-3 trial","volume":"32","author":"Angiolillo","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2022.09.053_bib28","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/CIRCULATIONAHA.120.048770","volume":"142","author":"Franchi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2022.09.053_bib29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12928-020-00719-6","volume":"36","author":"Watanabe","year":"2021","journal-title":"Cardiovasc Interv Ther"},{"key":"10.1016\/j.jcin.2022.09.053_bib30","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1210\/jc.2009-2392","article-title":"Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus","volume":"95","author":"Ertugrul","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jcin.2022.09.053_bib31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jdiacomp.2007.05.002","article-title":"Aspirin resistance associated with HbA1c and obesity in diabetic patients","volume":"22","author":"Cohen","year":"2008","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.jcin.2022.09.053_bib32","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2022.09.053_bib33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2022.09.053_bib34","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","article-title":"Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA","volume":"385","author":"Wang","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2022.09.053_bib35","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2022.09.053_bib36","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","article-title":"Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score","volume":"13","author":"Angiolillo","year":"2020","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2022.09.053_bib37","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.010007","article-title":"Patient selection and clinical outcomes in the STOPDAPT-2 trial: an all-comer single-center registry during the enrollment period of the STOPDAPT-2 randomized controlled trial","volume":"14","author":"Kanenawa","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2022.09.053_bib38","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jacc.2020.07.037","article-title":"Comparative trends in percutaneous coronary intervention in Japan and the United States, 2013 to 2017","volume":"76","author":"Inohara","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879822018805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879822018805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:17:28Z","timestamp":1761848248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879822018805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1936879822018805"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2022.09.053","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2022.09.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}